tirzepatide ada ADA: Once-Weekly Leads to Weight Loss in Patients With Obesity, T2D FDA says shortage of GLP-1

Beyond genetics, obesity itself reduces GLP-1 secretion in a harmful cycle: excess weight dampens L-cell function, lowering hormone production, which allows more overeating, which perpetuates weight gain

Research indicates that it promotes overall health, but its role in weight loss and skin radiance remains under study

Mood and well-being

Trial status: Active, not recruiting Clinical Trials Identifier: NCT06914895 Trial Name: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) Diabetes Type: Type 1 diabetes Trial Sponsor: Eli Lilly Why is this study important